Venatorx Pharmaceuticals

61 articles about Venatorx Pharmaceuticals

• VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio

  8/21/2019

  VenatoRx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team.

• VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row

  8/6/2019

  VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.

• HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections

  7/22/2019

  CDC estimates that antibiotic-resistant infections affect at least two million people in the United States each year and drive $35 billion in healthcare system costs annually.

• VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia

  6/20/2019

  VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.

• VenatoRx Pharmaceuticals to Present at ASM Microbe 2019

  6/17/2019

  VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA.

• VenatoRx Pharmaceuticals to Present Data for its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates at ECCMID 2019

  4/10/2019

  The 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 13-16, 2019 in Amsterdam, The Netherlands.

• VenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer

  4/4/2019

  VenatoRx Pharmaceuticals today announced that Lisa Wittmer, Ph.D. has joined the Company as Chief Development Officer.

• VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting

  3/25/2019

  VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting.

• VenatoRx Pharmaceuticals’ Christopher J. Burns, Ph.D. Named CEO of the Year by Life Sciences Pennsylvania

  3/14/2019

  Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry

• VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability

  2/28/2019

  Leveraging a Unique Small Molecule Library, VenatoRx seeks to open challenging bottlenecks for antibacterial drug discovery and successfully introduce new antibacterial agents into the clinic

• VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

  2/6/2019

  VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.

• Company Profile for VenatoRx Pharmaceuticals, Inc.

  1/15/2019

  VenatoRx Pharmaceuticals is a world leader in antibacterial and antiviral drug research and development. VenatoRx’s lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases.

• VenatoRx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for cefepime/VNRX-5133 at IDWeek 2018

  10/2/2018

  VenatoRx Pharmaceuticals will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133, at IDWeek 2018 which is taking place in San Francisco, CA this week from October 3-7, 2018.

• VenatoRx Pharmaceuticals named a 2018 Best Places to Work

  8/9/2018

  VenatoRx Pharmaceuticals announced that it was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.

• VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks

  5/31/2018

  The company will also present five posters featuring its lead clinical antibacterial candidate, cefepime/VNRX-5133

• VenatoRx Pharmaceuticals to Present at the 2018 UBS Global Healthcare Conference

  5/17/2018

  VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.

• VenatoRx Pharmaceuticals to Present in vitro and in vivo Data for cefepime/VNRX-5133 at ECCMID 2018

  4/12/2018

  Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23

• VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting

  3/19/2018

  President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT

• VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens

  1/4/2018

  VenatoRx announced that it has been awarded up to $16 million from the Defense Threat Reduction Agency (DTRA), an agency of the U.S. Department of Defense.

• VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program

  1/3/2018

  The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).